Healthcare

Share

Facebook Twitter Linkedin

Arch Biopartners Inc (TSXV:ARCH)

1.57 CAD

-0.010 0.633%

Last Updated at: 2024-09-13T19:41:00Z

Risk Disclaimer ARCH chart by TradingView

Back to TSXV:ARCH

Risk Disclaimer ARCH chart by TradingView

Sponsored Reports

Loading...

Previous Close (in CAD)	1.58
Change	-0.010 0.633%
52 W H/L (in CAD)	2.820/0.970
EBITDA (in CAD)	--
PE Ratio	--
Volume	5875
Diluted Eps TTM	-0.06

Total Assets (in CAD)	0.622M
Total Liabilities (in CAD)	5.092M
Revenue TTM (in CAD)	2.489M
Cash (in CAD)	0.506M
Market Cap (in CAD)	94.133 M
Revenue Per Share TTM	0.040
Gross Profit TTM (in CAD)	-0.503M

Summary

---

Income Statement

Balance Sheet

Change in Cash

Operating Cash

Arch Biopartners Inc

Arch Biopartners Inc., a biotechnology company, engages in the development of technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. Arch Biopartners Inc. is based in Toronto, Canada.

27 Street Clair Avenue East, Toronto, ON, Canada, M4T 2M5

647 428 7031

https://www.archbiopartners.com

Key Executives

Sr. No.	Name	Title	Year Born
1.	Mr. Richard Gabriel Muruve	Co-Founder, CEO, Pres & Director	1971
2.	Dr. Daniel Abraham Muruve	Co-Founder, Chief Science Officer & Member of Scientific Advisory Board	NA
3.	Mr. Andrew Bishop CFA	Acting CFO & Director	1966
4.	Dr. Justin MacDonald	Co-Founder & Principal Scientist	NA
5.	Dr. Paul Beck	Co-Founder & Principal Scientist	NA

Peers

Sector: Healthcare

Industry: Biotechnology

Company	Change (CAD)	Price (CAD)	Trailing PE(x)	Forward PE(x)	Price Sales TTM(x)	Price to Book Value(x)	Enterprise Value to Revenue(x)	Enterprise Value to EBITDA(x)
NGEN NervGen Pharma Corp	0.000 0.000%	2.53	0.000	0.000	0.000	29.478	0.000	-6.948
MIR MedMira Inc	0.000 0.000%	0.085	0.000	0.000	170.457	0.000	189.937	-48.737
TTI Thiogenesis Therapeutics Corp.	0.000 0.000%	0.71	0.000	0.000	0.000	11.863	0.000	-163.079
SBM Sirona Biochem Corp	0.000 0.000%	0.07	0.000	0.000	343.735	41.637	359.744	-13.882

• Income Statement
• Balance Sheet
• Cash Flow

Income Statement

(Currency in CAD)

Breakdown	30-09-2022	30-09-2021	30-09-2020	30-09-2019	30-09-2018
Income Before Tax	-1.389M	-1.17M	-4.629M	-2.358M	-3.198M
Minority Interest	-	-	-	-	-
Net Income	-1.389M	-1.17M	-4.629M	-2.358M	-3.198M
Selling General Administrative	0.773M	1M	2.567M	0.771M	1.734M
Gross Profit	-	-	-	-1.67M	-1.502M
Reconciled Depreciation	-	-	-	-	-
Ebit	-0.997M	-0.819M	-4.379M	-1.914M	-2.936M
Ebitda	-1.08M	-0.896M	-4.453M	-2.247M	-3.134M
Depreciation And Amortization	-	-	-	-	-
Operating Income	-1.08M	-0.892M	-4.458M	-2.252M	-3.168M
Other Operating Expenses	-	-	-	-	-
Interest Expense	0.309M	0.273M	0.176M	0.11M	0.064M
Tax Provision	-	-	-	-	-
Interest Income	-	-	-	-	-
Net Interest Income	-0.309M	-0.273M	-0.176M	-0.11M	-0.064M
Income Tax Expense	-	-	-	-	0M
Total Revenue	0M	3.887M	0.068M	0.094M	0M
Total Operating Expenses	1.08M	4.778M	4.526M	2.346M	3.168M
Cost Of Revenue	-	-	-	1.764M	1.502M
Total Other Income Expense Net	-	-0.005M	0.005M	0.004M	0.034M
Net Income From Continuing Ops	-1.389M	-1.17M	-4.629M	-2.358M	-3.198M
Net Income Applicable To Common Shares	-1.408M	-1.17M	-4.629M	-2.093M	-3.016M

Balance Sheet

(Currency in CAD)

Breakdown	30-09-2022	30-09-2021	30-09-2020	30-09-2019	30-09-2018
Total Assets	0.622M	2.668M	0.741M	0.568M	0.673M
Intangible Assets	-	-	-	-	-
Other Current Assets	-	-	-	-	0.182M
Total Liab	5.092M	6.551M	4.609M	3.47M	1.718M
Total Stockholder Equity	-4.471M	-3.882M	-3.868M	-2.902M	-1.046M
Other Current Liab	-	-	-	-	-
Common Stock	15.553M	14.758M	13.713M	12.027M	11.806M
Capital Stock	15.553M	14.758M	13.713M	12.027M	11.806M
Retained Earnings	-24.724M	-23.316M	-22.147M	-17.518M	-15.425M
Good Will	-	-	-	-	-
Other Assets	-	-	-	-	-
Cash	0.506M	0.448M	0.654M	0.4M	0.544M
Cash And Equivalents	-	-	-	-	-
Total Current Liabilities	2.779M	3.189M	1.219M	0.585M	0.278M
Current Deferred Revenue	-	-	-	-	-
Net Debt	3.906M	4.716M	2.737M	2.485M	0.939M
Short Term Debt	-	-	-	-	-
Short Long Term Debt	2.1M	1.802M	-	-	-
Short Long Term Debt Total	-	-	-	-	-
Other Stockholder Equity	-	-	-	0.015M	-
Property Plant Equipment	-	-	-	-	-
Total Current Assets	0.622M	2.668M	0.741M	0.833M	0.855M
Long Term Investments	-	-	-	-	-
Short Term Investments	-	-	-	-	-
Net Receivables	0.087M	2.201M	0.061M	0.14M	0.109M
Long Term Debt	2.313M	3.362M	3.39M	2.885M	1.483M
Inventory	-	-	-	-	-
Accounts Payable	0.489M	0.962M	0.949M	0.468M	0.227M
Accumulated Other Comprehensive Income	-	-	-	-	-
Non Currrent Assets Other	-	-	-	0M	0M
Non Current Assets Total	0M	0M	0M	0M	0M
Capital Lease Obligations	-	-	-	-	-
Long Term Debt Total	-	-	-	-	-

Cash Flow

(Currency in CAD)

Breakdown	30-09-2022	30-09-2021	30-09-2020	30-09-2019	30-09-2018
Investments	-	-	-	-	-
Total Cashflows From Investing Activities	-	-	-	-	-
Total Cash From Financing Activities	-0.421M	2.775M	2.158M	1.661M	2.654M
Net Income	-1.408M	-1.17M	-4.629M	-2.093M	-3.016M
Change In Cash	0.058M	-0.205M	0.253M	-0.144M	0.502M
Begin Period Cash Flow	0.448M	0.654M	0.4M	0.544M	0.043M
End Period Cash Flow	0.506M	0.448M	0.654M	0.4M	0.544M
Total Cash From Operating Activities	0.479M	-2.981M	-1.905M	-1.805M	-2.152M
Depreciation	-	-	-	-	-
Other Cashflows From Investing Activities	-	-	-	-	-
Dividends Paid	-	-	-	-	-
Change To Inventory	-	-	-	-	-
Sale Purchase Of Stock	-	-	-	-	-
Other Cashflows From Financing Activities	-	-	-	-0.003M	-0.015M
Capital Expenditures	0M	0M	0M	0M	0M
Change In Working Capital	-	-	-	-	-
Other Non Cash Items	-	-	-	-	-
Free Cash Flow	0.479M	-2.981M	-1.905M	-1.805M	-2.152M

No data found

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

• Top Gainer
• Top Loser